Peter B. Gilbert

31.8k total citations · 7 hit papers
309 papers, 11.8k citations indexed

About

Peter B. Gilbert is a scholar working on Virology, Infectious Diseases and Statistics and Probability. According to data from OpenAlex, Peter B. Gilbert has authored 309 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Virology, 110 papers in Infectious Diseases and 94 papers in Statistics and Probability. Recurrent topics in Peter B. Gilbert's work include HIV Research and Treatment (145 papers), Advanced Causal Inference Techniques (58 papers) and Statistical Methods and Inference (56 papers). Peter B. Gilbert is often cited by papers focused on HIV Research and Treatment (145 papers), Advanced Causal Inference Techniques (58 papers) and Statistical Methods and Inference (56 papers). Peter B. Gilbert collaborates with scholars based in United States, South Africa and Germany. Peter B. Gilbert's co-authors include Lawrence Corey, Stanley A. Plotkin, Michael G. Hudgens, M. Juliana McElrath, Ying Huang, Steven G. Self, David C. Montefiori, Max Essex, John R. Mascola and Ann Duerr and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Peter B. Gilbert

289 papers receiving 11.5k citations

Hit Papers

Efficacy assessment of a cell-mediated immunity HIV-1 vac... 2005 2026 2012 2019 2008 2005 2006 2021 2009 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    2008 1.2k citations Devan V. Mehrotra, Peter B. Gilbert et al. profile →
  2. Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
    2005 845 citations John R. Mascola, Leonidas Stamatatos et al. profile →
  3. Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand
    2006 569 citations Punnee Pitisuttithum, Peter B. Gilbert et al. profile →
  4. Evidence for antibody as a protective correlate for COVID-19 vaccines
    2021 475 citations Andrew Fioré-Gartland, Peter B. Gilbert et al. profile →
  5. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies
    2009 446 citations Holly Janes, Peter B. Gilbert et al. profile →
  6. A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines
    2022 109 citations Peter B. Gilbert et al. profile →
  7. Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
    2023 72 citations Peter B. Gilbert et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter B. Gilbert United States 51 5.9k 4.8k 3.2k 2.5k 2.5k 309 11.8k
Michael G. Hudgens United States 46 2.6k 0.4× 3.3k 0.7× 1.3k 0.4× 3.0k 1.2× 887 0.4× 293 8.7k
Richard A. Kaslow United States 61 7.5k 1.3× 6.6k 1.4× 6.0k 1.8× 6.8k 2.7× 1.5k 0.6× 221 19.8k
Steven G. Self United States 48 1.8k 0.3× 1.3k 0.3× 2.2k 0.7× 1.7k 0.7× 1.3k 0.5× 119 10.6k
Charles R. Rinaldo United States 66 9.4k 1.6× 8.0k 1.7× 6.6k 2.0× 7.2k 2.9× 1.8k 0.7× 347 19.6k
Joseph B. Margolick United States 64 12.9k 2.2× 10.2k 2.1× 4.8k 1.5× 4.1k 1.7× 2.3k 1.0× 257 19.7k
Martin Hirsch United States 72 13.0k 2.2× 13.6k 2.8× 3.8k 1.2× 7.2k 2.9× 1.9k 0.8× 274 24.1k
Alfred J. Saah United States 57 4.8k 0.8× 5.3k 1.1× 2.7k 0.8× 6.4k 2.6× 856 0.3× 165 13.6k
Glen A. Satten United States 45 4.7k 0.8× 7.1k 1.5× 487 0.2× 4.2k 1.7× 1.5k 0.6× 146 13.8k
Thomas C. Merigan United States 64 5.2k 0.9× 6.0k 1.3× 3.3k 1.0× 5.2k 2.1× 1.7k 0.7× 234 15.2k
Scott M. Hammer United States 52 10.2k 1.7× 12.3k 2.6× 908 0.3× 3.9k 1.5× 864 0.4× 129 16.0k

Countries citing papers authored by Peter B. Gilbert

Since Specialization
Citations

This map shows the geographic impact of Peter B. Gilbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter B. Gilbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter B. Gilbert more than expected).

Fields of papers citing papers by Peter B. Gilbert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter B. Gilbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter B. Gilbert. The network helps show where Peter B. Gilbert may publish in the future.

Co-authorship network of co-authors of Peter B. Gilbert

This figure shows the co-authorship network connecting the top 25 collaborators of Peter B. Gilbert. A scholar is included among the top collaborators of Peter B. Gilbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter B. Gilbert. Peter B. Gilbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Williamson, Brian D., et al.. (2024). Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens. PLoS ONE. 19(9). e0310042–e0310042.
2.
Sun, Yanqing, et al.. (2023). A Semiparametric Cox–Aalen Transformation Model with Censored Data. Biometrics. 79(4). 3111–3125. 2 indexed citations
3.
Lin, Dan-Yu, Yu Gu, Donglin Zeng, Holly Janes, & Peter B. Gilbert. (2021). Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases. 74(3). 544–552. 8 indexed citations
4.
Lin, Dan-Yu, Donglin Zeng, & Peter B. Gilbert. (2021). Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases. 73(10). 1927–1939. 16 indexed citations
5.
Zhao, Lue Ping, Terry P. Lybrand, Peter B. Gilbert, et al.. (2021). Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020—March 2021) Using a Statistical Learning Strategy. Viruses. 14(1). 9–9. 9 indexed citations
6.
Andersen‐Nissen, Erica, Andrew Fioré-Gartland, Lamar Ballweber-Fleming, et al.. (2021). Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathogens. 17(3). e1009363–e1009363. 20 indexed citations
7.
8.
Lin, Dan-Yu, Donglin Zeng, Devan V. Mehrotra, Lawrence Corey, & Peter B. Gilbert. (2020). Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. Clinical Infectious Diseases. 73(8). 1540–1544. 11 indexed citations
9.
Halloran, M. Elizabeth, Ira M. Longini, & Peter B. Gilbert. (2020). Designing a Study of Correlates of Risk for Ebola Vaccination. American Journal of Epidemiology. 189(8). 747–754. 2 indexed citations
10.
Duke, Elizabeth R., Brian D. Williamson, Bhavesh Borate, et al.. (2020). CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. Journal of Clinical Investigation. 131(1). 40 indexed citations
11.
Williamson, Brian D., Peter B. Gilbert, Marco Carone, & Noah Simon. (2020). Nonparametric variable importance assessment using machine learning techniques. Biometrics. 77(1). 9–22. 54 indexed citations
12.
Zhao, Hui, Qiwei Wu, Peter B. Gilbert, Ying Qing Chen, & Jianguo Sun. (2020). A regularized estimation approach for case‐cohort periodic follow‐up studies with an application to HIV vaccine trials. Biometrical Journal. 62(5). 1176–1191. 7 indexed citations
13.
Magaret, Craig A., David Benkeser, Brian D. Williamson, et al.. (2019). Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. PLoS Computational Biology. 15(4). e1006952–e1006952. 27 indexed citations
14.
Juraska, Michal, Craig A. Magaret, Jason Shao, et al.. (2018). Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proceedings of the National Academy of Sciences. 115(36). 48 indexed citations
15.
Huang, Yunda, Shelly Karuna, Lindsay N. Carpp, et al.. (2018). Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Human Vaccines & Immunotherapeutics. 14(9). 2116–2127. 17 indexed citations
16.
Pasin, Chloé, M. Elizabeth Halloran, Peter B. Gilbert, et al.. (2018). Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. PLoS ONE. 13(12). e0207878–e0207878. 5 indexed citations
17.
Huang, Yunda, Lily Zhang, Julie E. Ledgerwood, et al.. (2017). Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. mAbs. 9(5). 792–800. 26 indexed citations
18.
Fu, Rong & Peter B. Gilbert. (2016). Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling. Lifetime Data Analysis. 23(1). 136–159. 8 indexed citations
19.
Shepherd, Bryan E., Peter B. Gilbert, & Thomas Lumley. (2007). Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials. 102. 6 indexed citations
20.
Gilbert, Peter B., et al.. (1988). Obstetric care in the Keewatin. Changes in the place of birth 1971-1985.. PubMed. 47 Suppl 1. 481–4. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael G. Hudgens Breakdown of academic impact, for papers by Richard A. Kaslow Breakdown of academic impact, for papers by Steven G. Self Breakdown of academic impact, for papers by Charles R. Rinaldo Breakdown of academic impact, for papers by Joseph B. Margolick Breakdown of academic impact, for papers by Martin Hirsch Breakdown of academic impact, for papers by Alfred J. Saah Breakdown of academic impact, for papers by Glen A. Satten Breakdown of academic impact, for papers by Thomas C. Merigan Breakdown of academic impact, for papers by Scott M. Hammer
Rankless by CCL
2026